Javascript must be enabled to continue!
Comparison of 1‐week vs. 2‐ or 4‐week therapy regimens with ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication
View through CrossRef
Background: Helicobacter pylori eradication therapies based on ranitidine bismuth citrate have recently been introduced in clinical practice.Aim:To compare the efficacy of three regimens containing ranitidine bismuth citrate given for 1, 2 and 4 weeks, combined with two antibiotics for the first week, in the eradication of H. pylori.Methods:Eighty‐six consecutive patients (50 duodenal ulcer disease, 36 non‐ulcer dyspepsia) with H. pylori infection were offered three eradication regimens: (a) 1‐week group (n=28), ranitidine bismuth citrate 400 mg b.d. for 7 days; (b) 2‐week group (n=29), ranitidine bismuth citrate 400 mg b.d. for 14 days; and (c) 4‐week group (n=29), ranitidine bismuth citrate 400 mg b.d. for 28 days. In all patients, clarithromycin 500 mg b.d. and metronidazole 500 mg b.d. were given for the first week. Endoscopy was repeated 1 month after the end of treatment and eradication was considered to be successful if both rapid urease test and histology were negative.Results:Overall, H. pylori was eradicated in 84% (72/86) patients on intention‐to‐treat analysis, whereas the per protocol cure rate was 89% (72/81). Eradication rates were 23/27 (85%) (95% confidence interval (CI): 66–96%), 25/27 (92%) (95% CI: 76–99%) and 24/27 (89%) (95% CI: 71–98%) in the 1‐, 2‐ and 4‐week groups, respectively, on per protocol analysis, and 25/28 (82%) (95% CI: 63–94%), 25/29 (86%) (95% CI: 68–96%) and 24/29 (83%) (95% CI: 64–94%), respectively, on intention‐to‐treat analysis (P > 0.05, N.S.). No significant differences were observed between groups concerning duodenal ulcer healing, resolution of symptoms and adverse effects.Conclusions:The 1‐week regimen with ranitidine bismuth citrate, clarithromycin and metronidazole is effective in H. pylori eradication. Prolongation of treatment with ranitidine bismuth citrate for 2 or 4 weeks does not achieve a statistically significant more favourable outcome.
Title: Comparison of 1‐week vs. 2‐ or 4‐week therapy regimens with ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication
Description:
Background: Helicobacter pylori eradication therapies based on ranitidine bismuth citrate have recently been introduced in clinical practice.
Aim:To compare the efficacy of three regimens containing ranitidine bismuth citrate given for 1, 2 and 4 weeks, combined with two antibiotics for the first week, in the eradication of H.
pylori.
Methods:Eighty‐six consecutive patients (50 duodenal ulcer disease, 36 non‐ulcer dyspepsia) with H.
pylori infection were offered three eradication regimens: (a) 1‐week group (n=28), ranitidine bismuth citrate 400 mg b.
d.
for 7 days; (b) 2‐week group (n=29), ranitidine bismuth citrate 400 mg b.
d.
for 14 days; and (c) 4‐week group (n=29), ranitidine bismuth citrate 400 mg b.
d.
for 28 days.
In all patients, clarithromycin 500 mg b.
d.
and metronidazole 500 mg b.
d.
were given for the first week.
Endoscopy was repeated 1 month after the end of treatment and eradication was considered to be successful if both rapid urease test and histology were negative.
Results:Overall, H.
pylori was eradicated in 84% (72/86) patients on intention‐to‐treat analysis, whereas the per protocol cure rate was 89% (72/81).
Eradication rates were 23/27 (85%) (95% confidence interval (CI): 66–96%), 25/27 (92%) (95% CI: 76–99%) and 24/27 (89%) (95% CI: 71–98%) in the 1‐, 2‐ and 4‐week groups, respectively, on per protocol analysis, and 25/28 (82%) (95% CI: 63–94%), 25/29 (86%) (95% CI: 68–96%) and 24/29 (83%) (95% CI: 64–94%), respectively, on intention‐to‐treat analysis (P > 0.
05, N.
S.
).
No significant differences were observed between groups concerning duodenal ulcer healing, resolution of symptoms and adverse effects.
Conclusions:The 1‐week regimen with ranitidine bismuth citrate, clarithromycin and metronidazole is effective in H.
pylori eradication.
Prolongation of treatment with ranitidine bismuth citrate for 2 or 4 weeks does not achieve a statistically significant more favourable outcome.
Related Results
Impact of Common Anticoagulants on Complete Blood Count Parameters Among Humans
Impact of Common Anticoagulants on Complete Blood Count Parameters Among Humans
Abstract
Introduction
Among the most frequently used anticoagulants in hematological testing are tetra-acetic acid (EDTA), sodium citrate, and sodium heparin. However, there is a n...
THE CLINICAL CHARACTERISTICS, ENDOSCOPIC FINDINGS AND THE EFFICACY OF THE BISMUTH-CONTAINING QUADRUPLE REGIMEN INTREATMENT OF PATIENTS WITH HELICOBACTER PYLORIGASTRODUODENAL INFLAMMATORY AND ULCER AT CAN THO HOSPITAL OF UNIVERSITY OF MEDICINE AND PHARMACY
THE CLINICAL CHARACTERISTICS, ENDOSCOPIC FINDINGS AND THE EFFICACY OF THE BISMUTH-CONTAINING QUADRUPLE REGIMEN INTREATMENT OF PATIENTS WITH HELICOBACTER PYLORIGASTRODUODENAL INFLAMMATORY AND ULCER AT CAN THO HOSPITAL OF UNIVERSITY OF MEDICINE AND PHARMACY
Background: Helicobacter pylori causes inflammation of the gastric mucosa and is associated with many upper gastrointestinal diseases, including chronic gastritis, peptic ulcer dis...
The role of helicobacter pylori in coronary heart disease : laboratory, observational, and interventional studies
The role of helicobacter pylori in coronary heart disease : laboratory, observational, and interventional studies
<p dir="ltr"><b>Background</b></p><p dir="ltr">Helicobacter pylori (H. pylori) infects nearly half of the world's population and causes gastritis, pep...
The role of helicobacter pylori in coronary heart disease : laboratory, observational, and interventional studies
The role of helicobacter pylori in coronary heart disease : laboratory, observational, and interventional studies
<p dir="ltr"><b>Background</b></p><p dir="ltr">Helicobacter pylori (H. pylori) infects nearly half of the world's population and causes gastritis, pep...
Antofloxacin, a novel fluoroquinolone, as a component of bismuth quadruple therapy for Helicobacter pylori eradication: a prospective, open-label, randomized trial
Antofloxacin, a novel fluoroquinolone, as a component of bismuth quadruple therapy for Helicobacter pylori eradication: a prospective, open-label, randomized trial
Abstract
Background Currently, the eradication rate of Helicobacter pylori ( H. pylori ) is markedly decreasing due to some antibiotics resistance, including clarithromycin...
Different regimens for eradication of Helicobacter pylori infection in children: a randomized controlled trial
Different regimens for eradication of Helicobacter pylori infection in children: a randomized controlled trial
Abstract
Eradication of Helicobacter pylori (H. pylori) infection in children is challenging due to increased antibiotic resistance and decreased effectiveness of the cur...
Clinicopathological Characteristics and Endoscopic Features of Early Gastric Cancers Diagnosed After Helicobacter pylori Eradication
Clinicopathological Characteristics and Endoscopic Features of Early Gastric Cancers Diagnosed After Helicobacter pylori Eradication
Abstract
Background. Helicobacter pylori (H. pylori) infection is an important risk factor for developing gastric cancer. However, even after H. pylori eradication, early g...
Helicobacter pylori infection in peptic ulcer haemorrhage
Helicobacter pylori infection in peptic ulcer haemorrhage
In this overview, medical advice for routine clinical practice regarding peptic ulcer haemorrhage (PUH) is given, based on the extensive literature about Helicobacter pylori and th...

